Dr.Reddy’s Laboratories Ltd (RDY) Given Average Rating of “Hold” by Analysts

Shares of Dr.Reddy’s Laboratories Ltd (NYSE:RDY) have been given an average rating of “Hold” by the five analysts that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and one has assigned a buy recommendation to the company.

A number of equities analysts have commented on RDY shares. Citigroup cut Dr.Reddy’s Laboratories from a “neutral” rating to a “sell” rating in a report on Thursday, January 17th. CL King raised Dr.Reddy’s Laboratories from a “neutral” rating to a “buy” rating in a report on Monday, February 4th. TheStreet raised Dr.Reddy’s Laboratories from a “c+” rating to a “b” rating in a report on Friday, February 1st. Finally, Zacks Investment Research cut Dr.Reddy’s Laboratories from a “buy” rating to a “hold” rating in a report on Friday, January 18th.

Shares of Dr.Reddy’s Laboratories stock traded down $0.49 during mid-day trading on Wednesday, reaching $40.37. 131,086 shares of the stock traded hands, compared to its average volume of 213,735. Dr.Reddy’s Laboratories has a fifty-two week low of $28.13 and a fifty-two week high of $41.28. The stock has a market capitalization of $6.68 billion, a P/E ratio of 39.97 and a beta of 0.11. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.81 and a quick ratio of 1.26.

Dr.Reddy’s Laboratories (NYSE:RDY) last announced its earnings results on Friday, February 1st. The company reported $0.41 EPS for the quarter. Dr.Reddy’s Laboratories had a return on equity of 13.16% and a net margin of 11.64%. The business had revenue of $535.42 million during the quarter. As a group, research analysts anticipate that Dr.Reddy’s Laboratories will post 1.52 EPS for the current fiscal year.

Several large investors have recently bought and sold shares of the stock. BlackRock Inc. increased its holdings in shares of Dr.Reddy’s Laboratories by 14.0% in the fourth quarter. BlackRock Inc. now owns 1,978,415 shares of the company’s stock valued at $74,588,000 after purchasing an additional 242,856 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Dr.Reddy’s Laboratories by 0.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 921,688 shares of the company’s stock worth $34,751,000 after acquiring an additional 3,272 shares during the period. Renaissance Technologies LLC grew its position in Dr.Reddy’s Laboratories by 36.5% in the third quarter. Renaissance Technologies LLC now owns 783,300 shares of the company’s stock worth $27,102,000 after acquiring an additional 209,490 shares during the period. Northern Trust Corp grew its position in Dr.Reddy’s Laboratories by 3.9% in the fourth quarter. Northern Trust Corp now owns 415,086 shares of the company’s stock worth $15,649,000 after acquiring an additional 15,395 shares during the period. Finally, Charles Lim Capital Ltd purchased a new position in Dr.Reddy’s Laboratories in the fourth quarter worth approximately $15,525,000. 12.32% of the stock is owned by hedge funds and other institutional investors.

Dr.Reddy’s Laboratories Company Profile

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations.

Recommended Story: Fundamental Analysis and Individual Investors

Receive News & Ratings for Dr.Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr.Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.